A non-hormonal, soybean-derived API targeting the estrogen receptors — without being recognized by the body as estrogen.
The Femarelle® Line constitutes 3 products targeting the different symptoms that women suffer from, following estrogen decline:
With over 20 published studies DT56a was shown to act as a Selective Estrogen Receptor Modulator (SERM), with agonistic effects in tissues such as the brain and bone, while blocking estrogenic effects in reproductive tissues. Femarelle's effect is typically felt within the first month of use, and it was declared a first-line treatment for menopause management at the European Society of Gynecology Annual Congress in 2017.
- Femarelle® Rejuvenatefocuses on anti-aging, assisting women with the primary stages of the hormonal imbalance affecting their skin, hair and mood.
- Femarelle® Rechargefocuses on the classic symptoms associated with menopause, such as hot flushes, night sweats, sleep disturbance and loss of libido.
- Femarelle® Unstoppablefocuses on healthy aging, providing bone and vaginal health as well as increased energy levels.
DT56a® is a proprietary, plant-derived selective estrogen receptor modulator (SERM) with selective agonistic activity in the brain and bone, while exhibiting no estrogenic effects on the breast or uterus. Unlike hormone therapy, DT56a has not been shown to adversely affect blood clotting parameters, offering a favorable safety profile for menopause management. Backed by more than 20 published clinical and scientific studies in leading peer-reviewed journals and conducted by internationally recognized physicians and researchers, the Femarelle® line has been shown to help reduce menopausal symptoms, support bone health, and improve quality of life. Benefits are often experienced within the first month of use, providing effective symptom relief with a well-established safety profile and documented long-term use.
